Johnson&Johnson must pay $230 million for deceptive marketing

The pharmaceutical giant Johnson&Johnson has agreed to a settlement in a lawsuit brought against it by the state of New York, committing to pay $230 million and exit the opioid analgesics business in the U.S. market. New York Attorney General Letitia James filed the lawsuit against the company and several other manufacturers of controversial pain medications, claiming that they are responsible for the opioid addiction epidemic due to their sales and deceptive marketing.

According to data presented, this addiction has claimed around 800,000 lives over the past twenty years, and although, as she claims, nothing can compensate for the loss of any life, the funds obtained will be directed towards the prevention and treatment of addiction and the prevention of the epidemic.

Lawsuits are pouring in

Attorney General James primarily criticizes the pharmaceutical giant for aggressively promoting its prescription pain medications while downplaying the risks of use. Johnson&Johnson, in its statement, asserted that the settlement does not imply an admission of guilt and that its marketing communications have always been truthful and responsible. However, despite these claims, Johnson&Johnson has faced significant reputational issues in recent years, which could seriously jeopardize their business.

In fact, this pharmaceutical giant paid $465 million to the state of Oklahoma two years ago in a lawsuit that also accused them of the excessive use of pain medications. They are still facing lawsuits regarding their baby powder, which has been found to contain traces of asbestos (the company claims it is only one batch), and in a lawsuit concerning defective artificial hips, they have already paid one billion dollars. Earlier this year, they faced issues with the Covid-19 vaccine – due to human error, 15 million doses were ruined, prompting the company to temporarily halt production.

If the upcoming hearings and public reactions to media headlines regarding past cases are any indication, Johnson&Johnson has a long road ahead to repair its image and, most importantly, regain consumer trust.

{embed_digitalno_izdanje}{/embed_digitalno_izdanje}